Grektek was founded in March 2016 by InnovateTech Holdings, a Virginia firm that specializes in commercializing university technology. Two cardiologists from the University of Pittsburgh, Dr. G. Stuart Mendenhall and Dr. Matthew Jones, saw an opportunity to improve treatment of patients with cardiac arrhythmias and filed patents on devices and algorithms to support this opportunity.
InnovateTech Ventures hired Tom Klaff to advance the concept and the company, and Grektek was incorporated as the vehicle. Tom brought in Greg Eoyang, an experienced entrepreneur in mobile health, purchasing software assets of DaVinci, LLC, where Greg was the President and CTO.
Grektek combines the cardiac arrhythmia concepts envisioned by Drs. Mendenhall and Jones with the comprehensive patient monitoring software created by Greg into a powerful platform designed to help cardiac patients take better care of themselves.
In January of 2017, Grektek brought John McCauley on as CEO to move the business forward. John has invested in the business as well, because he sees the power of the platform and has friends and family who have been diagnosed with atrial fibrillation. Drs. Mendenhall and Jones continue as Advisors to Grektek to bring cardiologist expertise to the product.
In March of 2017, Grektek hired Joe Appelbaum to lead its Corporate Development function. Joe’s role is to build strategic relationships with insurance companies and medical institutions to help drive distribution and sales of the everbeat platform.
Grektek submitted a 510(K) request for clearance to the US Food & Drug Administration in early 2018 for everbeat version 1.
Grektek’s headquarters are located in Maryland, at 943 Willowleaf Way, Potomac, MD 20854.